Taro Pharmaceutical Industries Ltd

(NYSE:TARO)

Latest On Taro Pharmaceutical Industries Ltd (TARO):

Date/Time Type Description Signal Details
2023-05-27 06:58 ESTNewsTaro Pharma weighing offer from Sun Pharma to acquire company at $38 shareN/A
2023-05-26 02:24 ESTNewsTaro Pharmaceutical misses top and bottom line consensus for Q4N/A
2023-05-24 07:55 ESTNewsTaro Pharmaceutical misses top and bottom line consensus for Q1N/A
2023-02-24 09:00 ESTNewsTaro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate HoldN/A
2023-01-24 19:49 ESTNewsTaro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92MN/A
2023-01-05 00:19 ESTNewsJazz Pharma files patent infringement suit against Teva, Taro over generic EpidiolexN/A
2022-10-28 06:19 ESTNewsTaro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52MN/A
2022-10-26 23:11 ESTNewsTaro Pharmaceutical Q2 2023 Earnings PreviewN/A
2022-08-16 14:27 ESTNewsIntellipharmaceutics inks license deal with Taro for depression tablets desvenlafaxineN/A
2022-08-15 22:08 ESTNewsTaro Pharmaceutical hits 52-week low; down 28% YTDN/A
2022-08-15 22:08 ESTNewsHot Stocks: REV surges 30%; TRQ plunges; HRB sets 52-week high; TARO hits 52-week lowN/A
2022-08-12 08:21 ESTNewsTaro recalls certain lots of bone disorder drug in Canada on particulate matter concernsN/A
2022-07-28 00:27 ESTNewsTaro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8MN/A
2022-07-13 21:35 ESTNewsTaro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling CardN/A
2022-05-27 09:58 ESTNewsTaro Pharmaceutical GAAP EPS of $0.73, revenue of $143.26MN/A
2022-05-26 00:57 ESTNewsTaro Pharmaceutical Q1 2022 Earnings PreviewN/A
2022-02-22 11:04 ESTNewsTaro Pharmaceutical to acquire Alchemee from GaldermaN/A
2022-01-27 21:01 ESTNewsTaro Pharmaceutical GAAP EPS of $0.70 misses by $0.21, revenue of $138.98M misses by $3.24MN/A
2022-01-27 03:51 ESTNewsTaro Pharmaceutical Q3 2022 Earnings PreviewN/A
2021-12-02 05:33 ESTNewsTaro Pharmaceutical names new finance chiefN/A
2021-10-29 05:58 ESTNewsTaro Pharmaceutical EPS misses by $0.36, misses on revenueN/A
2021-10-04 13:43 ESTNewsTaro Pharmaceutical to pay $213M over price fixing allegtionsN/A
2021-07-28 10:37 ESTNewsTaro Pharmaceutical EPS beats by $0.25, beats on revenueN/A
2021-07-22 02:18 ESTNewsTaro Pharma's CFO Daphne Huang resignsN/A
2021-02-02 12:57 ESTAnalyst RatingThe Analyst Target Price has increased from $80 to $81.Buy
2021-01-30 08:39 ESTFinancialsCompany financials have been released.Neutral
2021-01-28 08:33 ESTEarnings EstimateAn EPS average of $0.82 is estimated for the quarter ending on June 30, 2021.Sell
2021-01-27 21:33 ESTNewsTaro Pharmaceutical EPS misses by $0.15, misses on revenueN/A
2020-11-26 21:43 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 09:12 ESTAnalyst RatingThe Analyst Target Price has decreased from $82 to $80.Neutral
2020-11-08 01:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:16 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 08:57 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 02:23 ESTNewsTaro Pharmaceutical EPS beats by $0.41, beats on revenueN/A
2020-11-01 02:14 ESTNewsTaro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call TranscriptN/A
2020-09-29 10:32 ESTNewsTaro Pharmaceutical launches generic Deferiprone in U.S.N/A
2020-09-26 14:10 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:23 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 10:16 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 05:48 ESTEarnings EstimateAn EPS average of $4.67 is estimated for the 2022 year.Buy
2020-08-06 14:03 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 09:39 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 10:08 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 18:01 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:58 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:58 ESTEarnings EstimateAn EPS average of $1.31 is estimated for the quarter ending on December 31, 2020.Buy
2020-07-30 05:12 ESTNewsTaro Pharmaceutical EPS of -$11.37N/A
2020-07-29 22:05 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 06:04 ESTAnalyst RatingThe Analyst Target Price has decreased from $96 to $82.Neutral
2020-07-27 13:54 ESTFinancialsCompany financials have been released.Neutral

About Taro Pharmaceutical Industries Ltd (TARO):

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

See Advanced Chart

General

  • Name Taro Pharmaceutical Industries Ltd
  • Symbol TARO
  • Type Common Stock
  • Exchange NYSE
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 1,464
  • Last Split Factor2:1
  • Last Split Date2001-07-27
  • Fiscal Year EndMarch
  • IPO Date1993-04-01
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.taro.com
View More

Valuation

  • Trailing PE 10.6
  • Forward PE 20.08
  • Price/Sales (Trailing 12 Mt.) 5.2
  • Price/Book (Most Recent Quarter) 1.7
  • Enterprise Value Revenue 3.33
  • Enterprise Value EBITDA 4.58
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$8.41
  • Next Year EPS Estimate $3.87
  • Next Quarter EPS Estimate $0.99
  • Profit Margin -53%
  • Operating Margin 29%
  • Return on Assets 4%
  • Return on Equity -17%
  • Revenue 575.56 million
  • Earnings Per Share $6.35
  • Revenue Per Share $15.04
  • Gross Profit 399.73 million
  • Quarterly Earnings Growth -5.1%
View More

Highlights

  • Market Capitalization 2.99 billion
  • EBITDA 187.02 million
  • Analyst Target Price $81
  • Book Value Per Share $46.00
View More

Share Statistics

  • Shares Outstanding 38.26 million
  • Shares Float 8.76 million
  • % Held by Insiders 7710%
  • % Held by Institutions 13.26%
  • Shares Short 128331
  • Shares Short Prior Month 122437
  • Short Ratio 4.23
  • Short % of Float 1%
View More

Technicals

  • Beta 1.03
  • 52 Week High $80
  • 52 Week Low $53.95
  • 50 Day Moving Average 75.5
  • 200 Day Moving Average 67.62
View More

Dividends

  • Dividend Date 2018-12-28
  • ExDividend Date 2018-12-10
  • Dividend Yield 0%
View More

Taro Pharmaceutical Industries Ltd (TARO) Dividend Calendar:

TARO's last dividend payment was made to shareholders on December 28, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Taro Pharmaceutical Industries Ltd (TARO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-01-27$N/A$0.86$1.01-14.85%
2020-09-302020-10-28$142.84 million$1.18$0.7753.25%
2020-06-302020-07-29$N/A-$11.37$1.16-1080.17%
2020-03-312020-05-19$174.94 million$1.42$1.53-7.19%
2019-12-312020-02-03$147.68 million$1.76$1.5414.29%
2019-09-302019-11-04$160.85 million$1.46$1.72-15.12%
2019-06-302019-08-08$161.3 million$1.72$1.96-12.24%
2019-03-312019-05-22$179.92 million$1.52$2.26-32.74%
2018-12-312019-02-07$176.38 million$2.40$1.9523.08%
2018-09-302018-11-05$158.97 million$1.60$1.96-18.37%
2018-06-302018-08-09$154.62 million$1.71$2.33-26.61%
2018-03-312018-05-17$175.22 million$2.17$1.5143.71%
2006-12-312007-03-20$252.27 million-$0.27$0.07-485.71%
2005-09-302005-11-17$72.54 million$0.07$0.28-75%
2005-06-302005-07-28$74.22 million$0.22$0.28-21.43%
2005-03-312005-04-26$78.54 million$0.17$0.21-19.05%
2004-12-312005-02-24$77.67 million$0.16$0.1233.33%
2004-09-302004-10-28$73.28 million$0.14$0.02600%
2004-06-302004-07-29$49.1 million-$0.31$0.44-170.45%
2004-03-312004-04-29$84.08 million$0.37$0.53-30.19%
2003-12-312004-02-17$88.62 million$0.56$0.551.82%
2003-09-302003-10-30$83.12 million$0.53$0.521.92%
2003-06-302003-07-24$74.75 million$0.50$0.500%
2003-03-312003-04-16$68.97 million$0.47$0.454.44%
2002-12-312003-02-20$61.98 million$0.44$0.424.76%
2002-09-302002-10-24$55.48 million$0.39$0.382.63%
2002-06-302002-07-23$49.58 million$0.35$0.329.38%
2002-03-312002-04-25$44.54 million$0.34$0.326.25%
2001-12-312002-02-21$43.46 million$0.34$0.319.68%
2001-09-302001-10-18$41.04 million$0.29$0.2611.54%
2001-06-302001-07-19$36.36 million$0.24$0.1560%
2001-03-312001-04-30$28.37 million$0.11$0.1010%
2000-12-312001-02-22$29.95 million$0.14$0.137.69%
1997-12-311998-03-13$0.01$0.05-80%
1996-06-301996-07-25$0.03$0.030%
1996-03-311996-04-29$0.01$0.010%
1995-09-301995-10-26$0.06$0.0450%
1994-12-311995-02-23$0.06$0.0450%
1994-09-301994-11-01$0.04$0.06-33.33%
1994-06-301994-08-02$0.05$0.0425%
1994-03-311994-05-11$0.03$0.01200%

Taro Pharmaceutical Industries Ltd (TARO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A 16.55 million N/A 15.8 million 15 million
Income Before Tax N/A 48.65 million N/A 68.34 million 70.55 million
Selling General Administrative N/A 24.07 million N/A 29.11 million 20.93 million
Gross Profit N/A 81.59 million N/A 102.27 million 94.13 million
Ebit N/A 46.75 million N/A 62.49 million 58.2 million
Operating Income N/A 40.96 million N/A 57.21 million 58.2 million
Income Tax Expense 6.1 million N/A 8.85 million N/A 2.87 million
Total Revenue N/A 142.84 million N/A 174.94 million 147.68 million
Cost of Revenue N/A 61.26 million N/A 72.67 million 53.56 million
Total Other Income Expense Net N/A 2.01 million N/A 4.5 million 12.35 million
Net Income From Continuing Operations N/A 45.06 million N/A 54.42 million 67.68 million
Net Income Applicable to Common Shares 32.92 million N/A -434.92 million N/A 67.68 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments 78.81 million N/A -44.4 million -116.9 million -107.42 million
Change to Liabilities N/A 483.96 million N/A 17.4 million 10.83 million
Total Cash Flow from Investing Activities N/A -46.02 million N/A -123.62 million -113.07 million
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A -157000 -26.83 million N/A
Change to Operating Activities N/A -3.46 million N/A 1.83 million 6.51 million
Change in Cash -33.25 million N/A 3.99 million -51.31 million -72.32 million
Total Cash from Operating Activities -112.26 million 64.11 million 49.6 million 98.65 million 40.75 million
Depreciation 5.79 million N/A 5.28 million 5.45 million 5.58 million
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory -990000 N/A 4.8 million -9.44 million -155000
Change to Account Receivables -42.37 million N/A -7.89 million 20.17 million -33.99 million
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A -19.81 million N/A -4.45 million -4.2 million
Capital Expenditures 3.83 million N/A 8.03 million 5.75 million 5.63 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A 627.36 million N/A 231.49 million 222.36 million
Total Stockholder Equity N/A 1.73 billion N/A 2.1 billion 2.06 billion
Other Current Liabilities 538.67 million 547.35 million N/A 193.87 million 177.14 million
Total Assets N/A 2.35 billion N/A 2.34 billion 2.29 billion
Common Stock 1.76 billion N/A 1.68 billion N/A 2.06 billion
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings N/A N/A N/A N/A N/A
Other Liabilities 37.17 million N/A 109.07 million N/A 8.18 million
Other Assets 167.01 million N/A 137.13 million N/A 147.51 million
Cash N/A 498.8 million N/A 513.35 million 509.36 million
Total Current Liabilities 584.08 million 587.32 million N/A 222.73 million 214.18 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 206.3 million N/A 209.23 million N/A 206.69 million
Total Current Assets 1.52 billion 1.49 billion N/A 1.53 billion 1.46 billion
Long Term Investments N/A 476.8 million N/A 459.64 million 479.05 million
Net Tangible Assets 1.76 billion N/A 1.68 billion N/A 2.06 billion
Short Term Investments N/A 543.2 million N/A 595.38 million 542.03 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory 169.53 million 167.21 million N/A 153.07 million 157.88 million
Accounts Payable 45.41 million 39.97 million N/A 28.86 million 37.04 million

Taro Pharmaceutical Industries Ltd (TARO) Chart:

Taro Pharmaceutical Industries Ltd (TARO) News:

Below you will find a list of latest news for Taro Pharmaceutical Industries Ltd (TARO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Taro Pharmaceutical Industries Ltd (TARO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1722.50CALL0 0291.5TRUE00
2024-05-17250CALL0 0250.97TRUE00
2024-05-17300CALL0 0180TRUE00
2024-05-17350CALL0 0117.53TRUE00
2024-05-17400CALL0 059.76TRUE00
2024-05-17450CALL0 00FALSE00
2024-05-17500CALL0 00FALSE00
2024-05-17550CALL0 00FALSE00
2024-05-17600CALL0 00FALSE00
2024-05-1722.50PUT0 00FALSE00
2024-05-17250PUT0 00FALSE00
2024-05-17300PUT0 00FALSE00
2024-05-17350PUT0 00FALSE00
2024-05-17400PUT0 00FALSE00
2024-05-17450PUT0 056.43TRUE00
2024-05-17500PUT0 0103.94TRUE00
2024-05-17550PUT0 0139.41TRUE00
2024-05-17600PUT0 0169.33TRUE00
2024-06-2122.50CALL0 0121.01TRUE00
2024-06-21250CALL0 0102.89TRUE00
2024-06-21300CALL0 071.5TRUE00
2024-06-21350CALL0 044.51TRUE00
2024-06-21400CALL0 031.29TRUE00
2024-06-21450CALL0 00FALSE00
2024-06-21500CALL0 00FALSE00
2024-06-21550CALL0 00FALSE00
2024-06-21600CALL0 00FALSE00
2024-06-2122.50PUT0 00FALSE00
2024-06-21250PUT0 00FALSE00
2024-06-21300PUT0 00FALSE00
2024-06-21350PUT0 00FALSE00
2024-06-21400.3PUT0 10FALSE00
2024-06-21450PUT0 025.61TRUE00
2024-06-21500PUT0 047.73TRUE00
2024-06-21550PUT0 064.66TRUE00
2024-06-21600PUT0 079.03TRUE00
2024-07-19200CALL0 0188.65TRUE00
2024-07-1922.50CALL0 077.07TRUE00
2024-07-19250CALL0 0143.53TRUE00
2024-07-19300CALL0 050.54TRUE00
2024-07-19350CALL0 029.74TRUE00
2024-07-19402.6CALL8 814.46TRUE2.60
2024-07-19450.2CALL0 1298.82FALSE00
2024-07-19500.45CALL0 240FALSE00
2024-07-19200PUT0 00FALSE00
2024-07-1922.50PUT0 00FALSE00
2024-07-19250PUT0 00FALSE00
2024-07-19300PUT0 00FALSE00
2024-07-19350.1PUT0 90FALSE00
2024-07-19400.25PUT0 6914.14FALSE00
2024-07-19450PUT0 00TRUE00
2024-07-19500PUT0 070.75TRUE00
2024-10-1822.50CALL0 0115.52TRUE00
2024-10-18250CALL0 0100.44TRUE00
2024-10-18300CALL0 074.62TRUE00
2024-10-18350CALL0 022.03TRUE00
2024-10-18402.5CALL0 1500TRUE00
2024-10-18450.2CALL0 165.37FALSE00
2024-10-18500CALL0 00FALSE00
2024-10-18550CALL0 00FALSE00
2024-10-18600CALL0 00FALSE00
2024-10-1822.50PUT0 00FALSE00
2024-10-18250PUT0 00FALSE00
2024-10-18300PUT0 00FALSE00
2024-10-18350PUT0 00FALSE00
2024-10-18400.3PUT0 110.5FALSE00
2024-10-18450PUT0 00TRUE00
2024-10-18500PUT0 050.37TRUE00
2024-10-18550PUT0 062.01TRUE00
2024-10-18600PUT0 071.82TRUE00

Latest TARO Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$35.2
Jun 13, 2022 7:59 PM EST81$35.11
Jun 13, 2022 7:59 PM EST19$35.11
Jun 13, 2022 7:59 PM EST1$35.11
Jun 13, 2022 7:59 PM EST5$35.08

Taro Pharmaceutical Industries Ltd (TARO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-1920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/906338/000156459020029846/0001564590-20-029846-index.htm
2015-07-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/906338/000000000015037874/0000000000-15-037874-index.htm
2015-08-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/906338/000000000015042769/0000000000-15-042769-index.htm
2019-11-25UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/906338/000000000019015841/0000000000-19-015841-index.htm
2020-01-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/906338/000000000020000502/0000000000-20-000502-index.htm
2020-03-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/906338/000000000020001939/0000000000-20-001939-index.htm
2020-05-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/906338/000000000020004002/0000000000-20-004002-index.htm
2020-05-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/906338/000000000020004352/0000000000-20-004352-index.htm
2020-02-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/906338/000094787120000134/0000947871-20-000134-index.htm
2014-11-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752314004574/0001157523-14-004574-index.htm
2014-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752314004876/0001157523-14-004876-index.htm
2015-02-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315000421/0001157523-15-000421-index.htm
2015-02-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315000502/0001157523-15-000502-index.htm
2015-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315001853/0001157523-15-001853-index.htm
2015-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315001903/0001157523-15-001903-index.htm
2015-07-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315002648/0001157523-15-002648-index.htm
2015-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315002827/0001157523-15-002827-index.htm
2015-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315002847/0001157523-15-002847-index.htm
2015-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315003168/0001157523-15-003168-index.htm
2015-10-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315003456/0001157523-15-003456-index.htm
2015-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315003668/0001157523-15-003668-index.htm
2015-11-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315003864/0001157523-15-003864-index.htm
2015-11-246-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315003920/0001157523-15-003920-index.htm
2015-12-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752315004117/0001157523-15-004117-index.htm
2016-02-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316004396/0001157523-16-004396-index.htm
2016-02-036-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316004423/0001157523-16-004423-index.htm
2016-02-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316004544/0001157523-16-004544-index.htm
2016-03-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316004934/0001157523-16-004934-index.htm
2016-05-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316005352/0001157523-16-005352-index.htm
2016-05-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316005693/0001157523-16-005693-index.htm
2016-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316005759/0001157523-16-005759-index.htm
2016-06-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316005850/0001157523-16-005850-index.htm
2016-06-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316005928/0001157523-16-005928-index.htm
2016-07-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316006047/0001157523-16-006047-index.htm
2016-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316006500/0001157523-16-006500-index.htm
2016-08-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316006570/0001157523-16-006570-index.htm
2016-09-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316006685/0001157523-16-006685-index.htm
2016-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316006815/0001157523-16-006815-index.htm
2016-10-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316007128/0001157523-16-007128-index.htm
2016-11-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316007315/0001157523-16-007315-index.htm
2016-11-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316007450/0001157523-16-007450-index.htm
2016-11-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316007457/0001157523-16-007457-index.htm
2016-12-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316007505/0001157523-16-007505-index.htm
2016-12-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316007592/0001157523-16-007592-index.htm
2016-12-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752316007629/0001157523-16-007629-index.htm
2017-01-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317000022/0001157523-17-000022-index.htm
2017-01-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317000255/0001157523-17-000255-index.htm
2017-02-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317000422/0001157523-17-000422-index.htm
2017-02-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317000483/0001157523-17-000483-index.htm
2017-05-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317001574/0001157523-17-001574-index.htm
2017-05-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317001634/0001157523-17-001634-index.htm
2017-06-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317001826/0001157523-17-001826-index.htm
2017-08-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317002324/0001157523-17-002324-index.htm
2017-09-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317002436/0001157523-17-002436-index.htm
2017-09-016-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317002437/0001157523-17-002437-index.htm
2017-10-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317002877/0001157523-17-002877-index.htm
2017-11-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317003044/0001157523-17-003044-index.htm
2017-11-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752317003142/0001157523-17-003142-index.htm
2018-01-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318000012/0001157523-18-000012-index.htm
2018-01-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318000174/0001157523-18-000174-index.htm
2018-02-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318000244/0001157523-18-000244-index.htm
2018-05-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318001106/0001157523-18-001106-index.htm
2018-05-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318001145/0001157523-18-001145-index.htm
2018-06-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318001330/0001157523-18-001330-index.htm
2018-08-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318001680/0001157523-18-001680-index.htm
2018-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318001792/0001157523-18-001792-index.htm
2018-09-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318001995/0001157523-18-001995-index.htm
2018-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318002180/0001157523-18-002180-index.htm
2018-11-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318002315/0001157523-18-002315-index.htm
2018-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318002340/0001157523-18-002340-index.htm
2018-12-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318002546/0001157523-18-002546-index.htm
2018-12-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752318002647/0001157523-18-002647-index.htm
2019-01-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752319000074/0001157523-19-000074-index.htm
2019-01-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752319000199/0001157523-19-000199-index.htm
2019-02-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752319000247/0001157523-19-000247-index.htm
2019-05-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752319001247/0001157523-19-001247-index.htm
2019-05-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752319001287/0001157523-19-001287-index.htm
2019-06-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752319001430/0001157523-19-001430-index.htm
2019-08-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752319001785/0001157523-19-001785-index.htm
2019-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752319002183/0001157523-19-002183-index.htm
2019-12-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000115752319002332/0001157523-19-002332-index.htm
2015-07-0120-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/906338/000119312515241661/0001193125-15-241661-index.htm
2015-07-28CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/906338/000119312515266184/0001193125-15-266184-index.htm
2019-11-15SC TO-ITender offer statement by Issuerhttps://www.sec.gov/Archives/edgar/data/906338/000119312519293464/0001193125-19-293464-index.htm
2019-12-03SC TO-I/ATender offer statement by Issuerhttps://www.sec.gov/Archives/edgar/data/906338/000119312519305368/0001193125-19-305368-index.htm
2019-12-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/906338/000119312519305377/0001193125-19-305377-index.htm
2019-12-17SC TO-I/ATender offer statement by Issuerhttps://www.sec.gov/Archives/edgar/data/906338/000119312519316301/0001193125-19-316301-index.htm
2019-12-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000119312519316304/0001193125-19-316304-index.htm
2019-12-20SC TO-I/ATender offer statement by Issuerhttps://www.sec.gov/Archives/edgar/data/906338/000119312519319505/0001193125-19-319505-index.htm
2016-06-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/906338/000156459016020459/0001564590-16-020459-index.htm
2017-06-2120-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/906338/000156459017012807/0001564590-17-012807-index.htm
2018-06-2120-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/906338/000156459018015952/0001564590-18-015952-index.htm
2019-06-2020-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/906338/000156459019022978/0001564590-19-022978-index.htm
2019-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459019040590/0001564590-19-040590-index.htm
2019-11-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459019043595/0001564590-19-043595-index.htm
2019-12-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459019046671/0001564590-19-046671-index.htm
2019-12-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459019046673/0001564590-19-046673-index.htm
2019-12-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459019047125/0001564590-19-047125-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020000779/0001564590-20-000779-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020003089/0001564590-20-003089-index.htm
2020-02-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020003756/0001564590-20-003756-index.htm
2020-02-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020005681/0001564590-20-005681-index.htm
2020-04-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020015435/0001564590-20-015435-index.htm
2020-04-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/906338/000156459020016218/0001564590-20-016218-index.htm
2020-05-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/906338/000156459020025671/0001564590-20-025671-index.htm
2020-05-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020026236/0001564590-20-026236-index.htm
2020-06-1920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/906338/000156459020029846/0001564590-20-029846-index.htm
2020-07-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020033276/0001564590-20-033276-index.htm
2020-07-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020034379/0001564590-20-034379-index.htm
2020-10-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020048410/0001564590-20-048410-index.htm
2020-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/906338/000156459020050361/0001564590-20-050361-index.htm